EL7.AI
StocksMedium•23 July 2026•
1 min read

Medpace Beats Q2 Expectations and Raises Full-Year 2026 Guidance

Key Facts

1Medpace reported Q2 2026 revenue of $707.3M, a 17.2% year-over-year increase.
2EPS reached $4.25 beating expectations, with the net book-to-bill ratio rebounding to 1.13x.
3The company raised its full-year 2026 revenue guidance to a range of $2.805B–$2.885B.

Reflecting robust demand within the clinical research sector, Medpace Holdings announced strong financial results for the second quarter of 2026. The company reported revenue of $707.3 million, marking a 17.2% increase year-over-year. Earnings per share reached $4.25, surpassing analyst expectations, while the net book-to-bill ratio rebounded to 1.13x, signaling an improved conversion rate of the company's backlog into active revenue.

These positive results arrive as the healthcare sector emphasizes operational efficiency, prompting Medpace to raise its full-year 2026 revenue guidance to a range of $2.805 billion to $2.885 billion. Per market data, this upward revision enhances revenue visibility and bolsters investor confidence in the company's ability to maintain growth momentum despite broader economic fluctuations.

Looking ahead, traders are focusing on the sustainability of backlog conversion rates as a primary catalyst for continued stock performance.